Abstract:BackgroundThe difference in restricted mean survival time (rmstDt∗$$ rmstD\left({t}^{\ast}\right) $$), the area between two survival curves up to time horizon t∗$$ {t}^{\ast } $$, is often used in cost-effectiveness analyses to estimate the treatment effect in randomized controlled trials. A challenge in individual patient data (IPD) meta-analyses is to account for the trial effect. We aimed at comparing different methods to estimate the rmstDt∗$$ rmstD\left({t}^{\ast}\right) $$ from an IPD meta-analysis.MethodsWe compared four methods: the area between Kaplan-Meier curves (experimental vs. control arm) ignoring the trial effect (Naïve Kaplan-Meier); the area between Peto curves computed at quintiles of event times (Peto-quintile); the weighted average of the areas between either trial-specific Kaplan-Meier curves (Pooled Kaplan-Meier) or trial-specific exponential curves (Pooled Exponential). In a simulation study, we varied the between-trial heterogeneity for the baseline hazard and for the treatment effect (possibly correlated), the overall treatment effect, the time horizon t∗$$ {t}^{\ast } $$, the number of trials and of patients, the use of fixed or DerSimonian-Laird random effects model, and the proportionality of hazards. We compared the methods in terms of bias, empirical and average standard errors. We used IPD from the Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma (MAC-NPC) and its updated version MAC-NPC2 for illustration that included respectively 1,975 and 5,028 patients in 11 and 23 comparisons.ResultsThe Naïve Kaplan-Meier method was unbiased, whereas the Pooled Exponential and, to a much lesser extent, the Pooled Kaplan-Meier methods showed a bias with non-proportional hazards. The Peto-quintile method underestimated the rmstDt∗$$ rmstD\left({t}^{\ast}\right) $$, except with non-proportional hazards at t∗$$ {t}^{\ast } $$= 5 years. In the presence of treatment effect heterogeneity, all methods except the Pooled Kaplan-Meier and the Pooled Exponential with DerSimonian-Laird random effects underestimated the standard error of the rmstDt∗$$ rmstD\left({t}^{\ast}\right) $$. Overall, the Pooled Kaplan-Meier method with DerSimonian-Laird random effects formed the best compromise in terms of bias and variance. The rmstDt∗=10years$$ rmstD\left({t}^{\ast },=,10,\kern0.5em ,\mathrm{years}\right) $$ estimated with the Pooled Kaplan-Meier method was 0.49 years (95 % CI: [−0.06;1.03], p = 0.08) when comparing radiotherapy plus chemotherapy vs. radiotherapy alone in the MAC-NPC and 0.59 years (95 % CI: [0.34;0.84], p < 0.0001) in the MAC-NPC2.ConclusionsWe recommend the Pooled Kaplan-Meier method with DerSimonian-Laird random effects to estimate the difference in restricted mean survival time from an individual-patient data meta-analysis.

An Alternative Approach for Estimating the Number Needed to Treat for Survival Endpoints.

Estimate Risk Difference and Number Needed to Treat in Survival Analysis.

[Number Needed to Be Screened in a Study: a Novel Measure for Disease Screening Effect].

Restricted Net Treatment Benefit in oncology

Scaling and interpreting treatment effects in clinical trials using restricted mean survival time

Number Needed to Treat in Multiple Sclerosis Clinical Trials

Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis

Quantifying absolute treatment effect heterogeneity for time-to-event outcomes across different risk strata: divergence of conclusions with risk difference and restricted mean survival difference

Statistical Considerations for Evaluating Treatment Effect under Various Non-proportional Hazard Scenarios

Quantifying treatment differences in confirmatory trials under non-proportional hazards

The use of restricted mean survival time to estimate treatment effect under model misspecification, a simulation study

Difference in Restricted Mean Survival Time: Small Sample Distribution and Asymptotic Relative Efficiency

Alternative Analysis Methods for Time to Event Endpoints under Non-proportional Hazards: A Comparative Analysis

Adjusted restricted mean survival times in observational studies

Semiparametric Additive Modeling of the Restricted Mean Survival Time

A univariable and multivariable analysis of right censored time-to-event data based on restricted mean survival time: A combination with traditional survival methods.

Meta-Analysis of Time-To-Event Outcomes from Randomized Trials Using Restricted Mean Survival Time: Application to Individual Participant Data

Implementation of an alternative method for assessing competing risks: restricted mean time lost

The use of restricted mean time lost under competing risks data

There is More to Length of Survival than Survival: Endpoints in Oncology Trials